More SYNTHAVERSE Spolka Akcyjna news
SYNTHAVERSE Spolka AkcyjnaGPW: SVE

Synthaverse Receives Marketing Authorization For Onko BCG Drug In The Netherlands

Nov 13, 2025 at 10:48 AM EST · Issued by SYNTHAVERSE Spolka Akcyjna

On 6ix: 6ix.com/news/synthaverse-receives-marketing-authorization-for-onko-bcg-drug-in-the-netherlands

Synthaverse SA GPW:SVE:

  • RECEIVES MARKETING AUTHORIZATION FOR ONKO BCG DRUG IN THE NETHERLANDS

SYNTHAVERSE Spolka Akcyjna on 6ix

Earlier from SYNTHAVERSE Spolka Akcyjna

  • Synthaverse H1 Net Loss At 5.3 Mln ZlotysOct 1, 2025
  • Synthaverse Signs Deal With Blau Farmaceutica For BCG 10 VaccineSep 29, 2025

Later from SYNTHAVERSE Spolka Akcyjna

  • Synthaverse Q3 Net Loss 7.7 Million ZlotysNov 28, 2025
  • Synthaverse Appoints Artur Chodkowski As CEOJan 14
  • Synthaverse Gets Marketing Authorization For Onko BCG In SerbiaMay 15
  • Synthaverse Receives Marketing Authorization For Onko BCG Medicinal Product In EcuadorMay 27
  • Synthaverse Q1 Net Loss 3.6 Million ZlotysMay 28
All SYNTHAVERSE Spolka Akcyjna news releases↗

Follow SYNTHAVERSE Spolka Akcyjna into a list and get an email when it puts out news.

Follow SYNTHAVERSE Spolka Akcyjna
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer